Article Text

Effects of living kidney donation on arterial stiffness: a systematic review protocol
  1. Rosendo A Rodriguez1,
  2. Mayra Trentin Sonoda2,
  3. Mohsen Agharazii3,
  4. Risa Shorr4,
  5. Kevin D Burns2
  1. 1Department of Medicine, The Ottawa Hospital, University of Ottawa, Ottawa, Ontario, Canada
  2. 2Division of Nephrology, Kidney Research Centre, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada
  3. 3Division of Nephrology, CHU de Québec-Université Laval Research Centre, Quebec City, Québec, Canada
  4. 4Learning Services, The Ottawa Hospital, Ottawa, Ontario, Canada
  1. Correspondence to Dr Rosendo A Rodriguez; rrodriguez1847{at}


Introduction Kidney donors have been reported to have accelerated progression of aortic stiffness and decreased glomerular filtration compared with healthy non-donors. This is a concern because increased aortic stiffness is an independent predictor of overall cardiovascular disease and all-cause mortality in the general population. To confirm if arterial stiffness increases after donation, we will systematically review all studies that evaluated indices of arterial stiffness in healthy individuals who underwent unilateral nephrectomy for kidney donation compared with age-matched healthy non-nephrectomised controls.

Methods/analysis We will comprehensively search for studies published between 1 January 1960 and 15 March 2021 in MEDLINE, EMBASE, Cochrane Central, OVID and EBM reviews. All prospective (cohort, case–control, case series and before-and-after studies) and retrospective non-randomised studies reporting indices of arterial stiffness in nephrectomised and non-nephrectomised healthy participants will be included. Primary outcome will be the difference in the functional metrics of arterial stiffness between donors and non-donors. Secondary outcomes will be the differences in systolic/diastolic blood pressures, serum creatinine, glomerular filtration, carotid artery intima–media thickness and vascular calcification. Study screening, selection and data extraction will be performed by two independent reviewers. Risk of bias will be independently assessed with the ROBINS-I tool and confidence in evidence by the Grading of Recommendations Assessment, Development and Evaluation recommendations. Qualitative and quantitative data syntheses as well as clinical and statistical heterogeneity (Forest plots, I2 and Cochran’s Q statistics) will be evaluated. If clinical and statistical heterogeneity are acceptable, inverse variance-weighted effects will be analysed by random effect models.

Ethics and dissemination No ethical approval is necessary. Our results will be disseminated through peer-review publication and presentations to guide stakeholders on the evaluation and follow-up care of kidney donors.

PROSPERO registration number CRD42020185551.

  • renal transplantation
  • transplant surgery
  • transplant medicine
  • clinical physiology
  • transplant surgery

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See:

Statistics from

Strengths and limitations of this study

  • This systematic review will synthesise best quality evidence on functional and structural components of arterial stiffness in kidney donors and age-matched healthy non-nephrectomised controls.

  • Since systemic blood pressure may be a determinant of arterial stiffness, its inclusion in a secondary analysis will improve our understanding on the potential relationship between blood pressure and arterial stiffness after donation.

  • Quality of evidence and differences in study design can limit the strength of our associations. To minimise misinterpretations, our study will implement well-validated scales for assessing risk of bias and confidence in cumulative evidence.


Live donor kidney transplantation is the preferred treatment for patients with end-stage renal disease (ESRD); it provides increased patient and graft survival and better quality of life than either dialysis or deceased donor transplantation.1 2 Every year, nearly 20 000 healthy adults worldwide accept the risk of donor nephrectomy to help family members, friends or even strangers to improve survival and quality of living.3 4 From a medical and ethical perspective, we ought to minimise their risks and maximise safety during and after kidney donation.

Although several studies2 5 6 have indicated that the absolute risk for healthy kidney donors following nephrectomy is very low, some have reported that unilateral nephrectomy is associated with an accelerated progression of aortic stiffness, enhanced left ventricular mass, interventricular septum thickness and decreased glomerular filtration compared with healthy non-donors matched by age and sex.7–11 In most of these reports, blood pressure at follow-up was not significantly different between donors and non-donors.8 9 12 13 Moreover, the risk of developing hypertension after donation was associated with higher blood pressure readings before donation, suggesting that reduced glomerular filtration rate (GFR) postdonation may be a graded risk factor for increased aortic stiffness, independent of blood pressure.7 13 These findings are clinically relevant because increased aortic stiffness as measured by carotid-femoral pulse wave velocity (cf-PWV) is a strong independent predictor of overall cardiovascular disease and all-cause mortality in the general population.14 An increase of 1 m/s in cf-PWV in an otherwise healthy individual has been associated with an adjusted risk increase of 14% and 15% in total cardiovascular events and all-cause mortality.14 Although compensatory renal hypertrophy and glomerular hyperfiltration occur after unilateral nephrectomy, a net decrease in total GFR typically follows, and this raises the possibility that cardiovascular disease risk after donation may become comparable to the risk in patients with mild to moderate chronic kidney disease.15–17 A reduction in renal function of such magnitude may be particularly critical for young living kidney donors who have the longest duration of risk exposure to the effects of reduced renal mass. To determine if kidney donors are at risk for increased aortic stiffness, a systematic appraisal of existing studies on arterial stiffness in donors compared with age-matched healthy controls is necessary. This review differs from existing systematic reviews and meta-analyses that have evaluated the interventional effects of kidney transplantation on arterial stiffness in kidney recipients with ESRD.18 19 The results of this new review can highlight strengths and weaknesses in previous studies with kidney donors and determine if there is a need for further well-designed investigations.


In this study, we will systematically review all non-randomised studies that evaluated central or peripheral arterial stiffness in healthy individuals who underwent unilateral nephrectomy after fulfilling standard criteria for kidney donation and who had measurements of the functional or structural components of arterial stiffness, as defined by validated metrics including: cf-PWV, brachial-ankle pulse wave velocity (PWV), pulse wave analysis, femoral-tibial PWV, ankle-brachial index, aortic distensibility, carotid artery intima–media thickness and vascular calcification. The major objective of this review will be to provide best quality evidence on whether arterial stiffness increases after living kidney donation beyond what is expected for age-matched healthy non-nephrectomised controls. We will primarily determine differences in functional markers of arterial stiffness between kidney donors and their respective comparative healthy non-donor controls. Since progression of arterial stiffness in kidney donors may be a determinant of cardiovascular outcomes, we will additionally compare arterial stiffness in donors before and after nephrectomy. Secondarily, we will document differences in systolic and diastolic blood pressure (SBP, DBP), serum creatinine, estimated GFR (eGFR) and structural markers of arterial stiffness (carotid intima–media thickness, arterial calcification scores) between these two populations.

Methods and analysis

We will conduct this review in accordance with the Cochrane Collaboration principles for Systematic Reviews20 and this protocol has been registered in the PROSPERO register for systematic reviews.21 The preferred reporting items for systematic Reviews described by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines22 will be followed and a checklist file for these recommendations will be included (online supplemental appendix 1).23

Population and eligibility criteria

Kidney donors

We will include healthy adults (≥18 years old) of any age who underwent unilateral nephrectomy after meeting standard screening criteria for organ donation and whose arterial stiffness was measured non-invasively before and/or after nephrectomy with any of the following functional metrics of arterial stiffness: cf-PWV, brachial-ankle PWV, femoral-tibial PWV, ankle-brachial index, pulse wave analysis (augmentation index and central pulse pressure) and aortic distensibility.24 25 As indicators of structural change in vascular stiffness, measurements of carotid artery intima–media thickness and vascular calcification scores will also be documented.26

Healthy controls

As controls, we will include adult individuals (≥18 years of age) with measurements of validated indices of arterial stiffness who participated as healthy comparative controls in kidney donor studies.7 8


In this review, uneventful unilateral nephrectomy for kidney donation independent of the surgical approach (laparoscopic and open nephrectomy) will be considered as the main intervention.


The primary outcome will be the difference in the functional metrics of arterial stiffness between healthy nephrectomised and non-nephrectomised participants as well as the difference in donors before and after nephrectomy. The absolute values in addition to between-group mean differences will be documented in their respective units of measurement. Secondary outcomes will be the differences in SBP and DBP (mm Hg), pulse pressure (mm Hg), serum creatinine levels (µmol/L), eGFR (ml/min/1.73 m2), carotid artery intima–media thickness (mm) and vascular calcification (scores).16 24 26 27 Clinical outcomes and any additional measures of endothelial function will be documented and reported accordingly.17 28

cf-PWV reference group

In addition to the primary comparative analysis, we will search for studies that measured cf-PWV in different healthy populations worldwide and who have reported values of normal cf-PWV standardised by age.29 We expect that this analysis will improve the generalisability of this review.

Study design

Since prospective randomised clinical trials of donation would never be possible for ethical reasons, only prospective non-randomised (cohort, case–control, case series and before-and-after studies) and retrospective studies will be included, provided that 10 or more subjects have participated in the primary analysis.

Search strategy

Our search strategy will be conducted using MEDLINE, EMBASE, Cochrane Central databases, CADTH’s ‘Grey matters light’, OVID, EBM reviews, Health Technology Assessment database and other grey literature of studies including government reports and policy statements published after 1 January 1960. A comprehensive search strategy will be constructed and implemented by a health information specialist (RS) with systematic review experience, in collaboration with the research team. MeSH terms will be used to capture the principal elements of the research question and identified citations will be exported to an excel spreadsheet for study review and selection. Our proposed literature search strategy is outlined in online supplemental appendix 2. Our planned systematic search will proceed until 15 March 2021. Manual review of the reference lists for all studies will be conducted according to predefined screening criteria (table 1). A final ‘grey literature’ search will be conducted using ‘Google Scholar’ as well as reviews of for any current study. No language restriction will be used in any of the initial search, but our final analysis will be restricted to articles reported in English, French, Italian, Portuguese and Spanish languages. Duplicate citations will be removed and search strategies will be kept up to the time of the end of this review.

Table 1

List of inclusion and exclusion criteria for the selection of comparative groups

Study screening, exclusions and selection

During the screening phase, we will include all prospective and retrospective non-randomised studies reporting measurements of arterial stiffness in nephrectomised and non-nephrectomised healthy participants. An iterative process of study selection will be followed using the inclusion and exclusion criteria set out in table 1. We will exclude studies reporting on investigations in paediatric populations (age <18 years), non-human studies, narrative reviews, in vitro or mathematical modelling reports, abstracts or conference proceedings and any duplicate or substudy of previously published investigations. All review processes will be independently performed by two individuals, with a third person available for consensus in cases of discrepancies.

All citations will first be screened by title and abstract. After selection by title/abstract and with the purpose of facilitating a final decision on eligible studies, an intermediate screening of the material and methods section will be implemented in duplicate to confirm the type of methodology employed for measuring arterial stiffness. A judicious decisive selection before data extraction will be achieved by the independent reviewers at the full-text level. In cases of missing information, we will consider contacting study authors. Neither of the review authors will be blinded to the journal titles or to the study authors or institutions.

Data extraction

A data extraction form will be prepared a priori with consensus from all investigators and optimised using a subset of 4 randomly selected studies prior to duplicate extraction by two independent reviewers. When multiple publications arise from one study, relevant data will be extracted into a single form. Data extraction will include: (1) study characteristics, design and methods: title, authors, journal/source/year, language of publication, country, type of study design, study period, publication status, total number of donors and non-donors, inclusion and exclusion criteria, and points of measurement; (2) sample characteristics: age, sex, age at time of nephrectomy, age at time of assessment, duration of follow-up and type of arterial stiffness instrumentation; (3) outcomes: change in arterial stiffness based on the metric of measurement: cf-PWV, brachial-ankle PWV, femoral-tibial PWV, ankle-brachial index, augmentation index, central pulse pressure, aortic distensibility, carotid artery intima–media thickness; arterial calcification scores, serum creatinine levels, eGFR, SBP, DBP and pulse blood pressure. We will document if arterial stiffness values are reported as adjusted or non-adjusted according to changes in mean arterial blood pressure and/or heart rate. If reported, we will document type and number of medications for the control of blood pressure.

Risk assessment of bias

Risk of bias for non-randomised studies will be assessed using the Risk of Bias in Non-Randomised studies (ROBINS-I) tool.30 Seven domains through which bias might be introduced will be independently evaluated and discussed by two reviewers, encompassing confounding, selection of participants (nephrectomised and non-nephrectomised), classification of the intervention (ie, unilateral nephrectomy), deviation from the intended intervention, missing data, measurement of outcomes and selection of the reported results. Each domain will be judged as either low, moderate, serious or critical risk of bias or no information available. After discussion among reviewers, an overall assessment of study bias with inclusion of all domains will be tabulated. Unresolved disagreements will be resolved with participation of a third reviewer.

Data synthesis and analysis plan

Studies will be included in qualitative and quantitative syntheses if they fulfil all eligibility criteria. Study characteristics will be summarised using means and SD or median and interquartile ranges for continuous variables and numbers and percentages for categorical variables. A narrative report of study characteristics will also be provided. We will identify potential sources of clinical heterogeneity according to differences in study design characteristics, methodological quality, characteristics at baseline between nephrectomised groups and their controls, and duration of follow-up periods. If at least two studies report on the same outcome, a quantitative analysis (ie, meta-analysis) will be attempted on those studies. Statistical heterogeneity will be characterised with Forest plots, the I2 and Cochran’s Q statistics (p<0.10). If both clinical and statistical heterogeneity are acceptable, inverse variance-weighted effects meta-analysis will be performed. An I2 value less than 60% with a non-significant χ2 statistic (p>0.10) will be suggestive of moderate statistical heterogeneity. We will primarily choose the random effects model according to the methodology of DerSimonian and Laird,31 but a fixed-effects meta-analysis will also be modelled as part of our sensitivity analysis. Based on the scale of measurements, we may choose to calculate pooled effect estimates using either standardised or mean differences and their corresponding 95% confidence intervals. To minimise the ‘double counting’ error in before-and-after studies, half of the total number of study participants will be allocated to each study arm. All analysis will be performed using RevMan V.5.3 (The Nordic Cochrane Centre, The Cochrane Collaboration, 2014, Copenhagen).

Sensitivity analysis

Depending on the number of eligible studies, sensitivity analyses may be performed to evaluate the effects of extreme values, high risk of study bias, and any confounding effects associated with differences in the reporting of adjusted or non-adjusted values of arterial stiffness according to changes in mean arterial pressure and/or heart rate. An analysis of the differences between fixed and random effects models on the pooled effect estimates will also be assessed.

Subgroup analysis

Clinical studies32 have documented that living donors genetically related to their ESRD recipients are more likely to develop the primary kidney disease. Thus, it is critical to differentiate the effects of unilateral nephrectomy on arterial stiffness between recipient-related healthy controls and those who are not related to the recipient. To minimise bias in our review and depending on the number of eligible studies, nature and detail of the reported information, we will attempt to determine the effects of potential confounders by performing subgroup analyses based on age, surgical technique (open vs laparoscopic nephrectomy), duration of follow-up after nephrectomy (short vs long-term), type of comparator (recipient related vs non-recipient -related), number and type of medications used for the control of blood pressure and sex according to different male to female ratios. Intergroup differences will be analysed using the Cochran’s Q statistics with p≤0.10.

Confidence in cumulative evidence

To assess the certainty in the evidence and strength of recommendations on the effects of unilateral nephrectomy in kidney donors, two reviewers will evaluate quality of evidence for each outcome measure according to the five domains of Grading of Recommendations Assessment, Development and Evaluation recommendations.33


Any protocol amendments will be summarised in the form of a table, where date of amendment, description of changes and rationale will be provided.

Patient and public involvement

Patients and/or the public were not involved in the design of the protocol.


Because living kidney donors are selected among the healthiest individuals, the long-term risk of ESRD, cardiovascular disease or death has been reported to be similar to or even lower than that in the general population.6 It has been documented, however, that unilateral nephrectomy frequently leads to reduced kidney function and variable levels of increased serum creatinine.5 15 16 Although the medium-term and long-term adverse effects of hyperfiltration and compensatory hypertrophy after donation remain unclear, endothelial dysfunction associated with decreased brachial artery reactivity17 34 and increased levels of uremic toxins35 have been reported in kidney donors. More recently, some studies have reported that unilateral nephrectomy leads to an increase in aortic stiffness, left ventricle mass and decreased GFR as early as 1 year after surgery.7–9 Although blood pressure was not markedly affected in these studies, initial results suggest that reduced GFR may be an independent graded risk factor for increased aortic stiffness and adverse left ventricle remodelling, independent of blood pressure.8 11 12

To characterise the haemodynamic effects of unilateral nephrectomy in kidney donors, we propose to systematically identify, appraise and summarise all non-randomised studies that have investigated indices of arterial stiffness before and after nephrectomy in donors to determine any increase in the progression of arterial stiffness compared with age-matched healthy individuals. In addition to improving our understanding of the relationship between reduced kidney function after donation and cardiovascular function, our findings will determine if unilateral nephrectomy is a risk factor for increased arterial stiffness in donors and whether non-invasive metrics of arterial stiffness could be useful for risk stratification.

Animal studies have shown that alterations in renal development resulting in reduced nephron number in the offspring result in blood pressure elevation, reduced cardiac functional reserve and left ventricle hypertrophy in adulthood.36 Although alterations of the renin–angiotensin–aldosterone system and changes in vascular tone are frequently present after unilateral nephrectomy,37 kidney donation is not considered a risk factor for hypertension post-donation. Kasiske et al38 followed living kidney donors for a 3-year period and identified an increase in blood pressure over time, but differences between donors and controls were non-significant. Kim et al39 found that there was an increase in blood pressure after donation with 21% of donors requiring medication for control of hypertension. Thiel et al13 reported that the risk of developing hypertension (defined as >140/90 mm Hg) increased 3.6-fold 1-year postdonation, but baseline values of kidney donors who became hypertensive were significantly higher than those who were less susceptible to hypertension. Because systemic blood pressure may be a determinant of arterial stiffness, we will include SBP and DBP as a secondary outcome. This will add to the understanding of the potential relationship between blood pressure and arterial stiffness following organ donation.37–39

To accept that increased arterial stiffness is associated with the effects of unilateral nephrectomy, convincing evidence based on good-quality studies and adequate methodological designs is critical. Although quality of evidence and differences in study design are factors that may limit the strength of our associations, implementing well-validated scales in our study for the assessment of risk of bias and certainty of evidence will minimise misinterpretations.30 33 In cases where information is not available, we will make every possible effort to contact the primary author(s) to obtain any missing information.

Living kidney donors obtain no medical benefit from donation, exposing themselves to health risks associated with the surgical procedure and the effects of reduced renal mass for the benefit of another human being. Promotion of donor autonomy in the medical decision-making process requires accurate quantification of the mid and long-term risks after donation. This is particularly critical for young living donors who have the longest risk of exposure.39 40 Our review will provide a more accurate estimate of the ‘short-to-mid-term’ risks of cardiovascular disease after donation by examining the progression of arterial stiffness postnephrectomy.37–41 Such results can inform potential donors and may guide their follow-up care and preserve good health in the long -term.

Ethics and dissemination

No ethics approval is required for this systematic review. Our findings will be disseminated through peer-review publication and presentation, which can inform clinical guidelines and management of potential kidney donors.


Supplementary materials

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.


  • Contributors RAR and KDB conceived and designed the study; RAR created the analytical plan and drafted the protocol; RAR and RS designed the search strategy; RAR, MTS, MA and KDB will be involved in one or more of the following tasks: study screening and selection, data extraction, verification, quality appraisal, synthesis, analysis of the evidence and data interpretation. All authors have read, reviewed and approved the final version of the manuscript. RAR is the guarantor.

  • Funding This work is supported by Kidney Research Centre, Ottawa Hospital Research Institute, University of Ottawa.

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.